Caladrius Biosciences Inc
CLBS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.35M
Close$
Share Statistics
| Market cap | $3.35 Million |
|---|---|
| Enterprise Value | $-9,708,632.00 |
| Dividend Yield | $0.56 (-) |
| Earnings per Share | $-1.91 |
| Beta | 0.91 |
| Outstanding Shares | 9,006,000 |
Return
| Return on Equity | -149.65% |
|---|---|
| Return on Assets | -116.30% |
| Return on Invested Capital | 39.55% |
Valuation & Multiples
| P/E Ratio | -1.79 |
|---|---|
| PEG | 35.98 |
| Price to Sales | - |
| Price to Book Ratio | 0.43 |
| Enterprise Value to Revenue | -57.11 |
| Enterprise Value to EBIT | -2.28 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Caladrius Biosciences Inc
CEO: David Mazzo Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mec...